# NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer

> **NCT03259035** · PHASE2 · COMPLETED · sponsor: **Canadian Cancer Trials Group** · enrollment: 58 (actual)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Folfox Protocol
- **DRUG:** Capox

## Key facts

- **NCT ID:** NCT03259035
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-29
- **Primary completion:** 2024-04-08
- **Final completion:** 2024-04-25
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03259035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03259035, "NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03259035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*